EUCTR2006-003451-20-DE进行中（未招募）不适用
Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct - TUD-Glivec-012
Technical University Dresden0 个研究点目标入组 44 人开始时间: 2006年12月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically/Cytologically confirmed diagnosis of advanced / metastatic carcinoma of the gallbladder or bill duct, which is unresectable or metastatic and therefore incurable with any conventional multimodality approach.
- •2. Performance status 0, 1 or 2 (ECOG)
- •3.Written, voluntary informed consent
- •4.Age > 18 years
- •5.Adequate bone marrow function (Granulocytes > 1,5 x 109/l, Hb > 10 g/dl, Platelets > 100 x 109/l)
- •6.Adequate hepatic and renal function ( bilirubin < 1,25 x upper normal limit or < 1,5 x upper normal limit if hyperbilirubinemia is related to underlying disease, ALAT + ASAT < 1,5 x upper normal limit, in case of liver metastases < 5 x upper normal limit, creatinine < 1,25 x upper normal limit)
- •7.Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Female patients with child-bearing potential must perform a highly effective barrier method of birth control throughout the study with a proven efficacy of >99%. The contraception treatment should be performed for an additional six month following discontinuation from study treatment. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following discontinuation of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient has received any other investigational agents within 28 days of first day of study drug dosing.
- •2.Patient is < 5 years free of another primary malignancy, except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ.
- •3.Female patients who are pregnant or breast-feeding.
- •4.Patient has a severe and/or uncontrolled medical disease.
- •5.The concurrent use of warfarin or acetaminophen are not allowed with imatinib mesylate and need to be replaced by other medications (e.g. by low molecular heparins in case of warfarin).
- •6.Radiotherapy or any major abdominal or thoracic surgery < 4 weeks before study entry (excluding diagnostic biopsy or port implantation)
- •7.Patient has received neoadjuvant imatinib mesylate or fluoropyrimidines prior to study entry
- •8.Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
- •9.Known incompatibility of imatinib,5-FU, or leucovorin
- •10.Known brain metastases
- •11.Concurrent systemic chemotherapy, immuntherapy, hormone therapy
- •12.History of severe psychiatric illness
- •13.Drug- or alcohol abuse
- •14.Patient has know chronic liver disease (i.e., chronic active hepatitis, and cirrhosis)
- •15.Patients with dihydropyrimidine dehydrogenase deficiency (i.e. Treatment with Zostexâ)
- •16.Patients that are associated with or dependend of the investigator or sponsor
- •17.Patients with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
- •18.Patients with a creatinine clearance of < 50ml/min.
- •19.Patients with a severe decrease of bone marrow function
- •20.Patients with acute infections
- •21.Patients with severe decrease of liver function
- •22.Patients in reduced performance status (ECOG > 2)
- •23.No active vaccinations should be peformed while being on study treatment
- •24.Anemia caused by vitamin B12 deficiency
研究者
相似试验
进行中（未招募）
不适用
Etude de phase II évaluant une chimiothérapie combinant doxorubicine, cyclophosphamide, vindésine et acide valproïque dans les cancers bronchiques à petites cellules réfractaires ou récidivant après une chimiothérapie comportant des dérivés du platine et de l’étoposide. - ELCWP1081les cancers bronchiques à petites cellulesEUCTR2009-015105-39-FRCentre Hospitalier Universiatire de Lille43
进行中（未招募）
不适用
Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.Type-I Diabetes Mellitus in renal trasplant patientsMedDRA version: 8.1Level: ptClassification code 10061835EUCTR2005-004523-19-ESÁrea de Trasplante y Terapia Celular - Hospital Central de Asturias10
进行中（未招募）
1 期
Phase III clinical trial to evaluate the efficacy and safety of inhaled ethanol in the treatment of early-stage COVID-19.COVID-19EUCTR2020-001760-29-ESSociedad Española de Farmacia Hospitalaria156
进行中（未招募）
1 期
Clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with phosphomannomutase deficiency.Cerebellar syndromeMedDRA version: 19.1Level: PTClassification code 10008072Term: Cerebellar syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-000810-44-ESFundació Sant Joan de Déu30
进行中（未招募）
1 期
Study to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphismsMetastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001508-45-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)100